A detailed history of Capital Fund Management S.A. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Capital Fund Management S.A. holds 111,572 shares of NBIX stock, worth $14 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
111,572
Previous 56,951 95.91%
Holding current value
$14 Million
Previous $7.84 Million 63.84%
% of portfolio
0.04%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$114.58 - $153.15 $6.26 Million - $8.37 Million
54,621 Added 95.91%
111,572 $12.8 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $7.45 Million - $8.15 Million
56,951 New
56,951 $7.84 Million
Q2 2021

Aug 12, 2021

SELL
$89.43 - $102.27 $5.39 Million - $6.16 Million
-60,266 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $3.54 Million - $4.82 Million
40,409 Added 203.5%
60,266 $5.86 Million
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $244,217 - $304,407
-2,810 Reduced 12.4%
19,857 $1.9 Million
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $320,116 - $449,914
3,329 Added 17.21%
22,667 $2.18 Million
Q2 2020

Aug 13, 2020

SELL
$85.09 - $130.36 $366,312 - $561,199
-4,305 Reduced 18.21%
19,338 $2.36 Million
Q1 2020

May 13, 2020

BUY
$75.11 - $113.76 $1.78 Million - $2.69 Million
23,643 New
23,643 $2.05 Million
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $581,040 - $703,598
-6,932 Closed
0 $0
Q2 2019

Aug 12, 2019

BUY
$72.24 - $91.27 $260,930 - $329,667
3,612 Added 108.8%
6,932 $585,000
Q1 2019

May 13, 2019

SELL
$69.31 - $91.53 $1.5 Million - $1.99 Million
-21,712 Reduced 86.74%
3,320 $292,000
Q4 2018

Feb 13, 2019

BUY
$68.32 - $124.36 $938,170 - $1.71 Million
13,732 Added 121.52%
25,032 $1.79 Million
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $1.12 Million - $1.42 Million
11,300 New
11,300 $1.39 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.